We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Monoclonal Antibody 100% Effective Against Marburg Virus
News

Monoclonal Antibody 100% Effective Against Marburg Virus

Monoclonal Antibody 100% Effective Against Marburg Virus
News

Monoclonal Antibody 100% Effective Against Marburg Virus

Colorized electron micrograph of Marburg virus.Dr. Tom Geisbert, University of Texas Medical Branch
Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Monoclonal Antibody 100% Effective Against Marburg Virus"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Scientists funded by the National Institutes of Health have found that an experimental treatment cured 100 percent of guinea pigs and rhesus monkeys in late stages of infection with lethal levels of Marburg and Ravn viruses, relatives of the Ebola virus. Although the Marburg and Ravn viruses are less familiar than Ebola virus, both can resemble Ebola in symptoms and outcomes in people, and both lack preventive and therapeutic countermeasures.


The study involved giving the animals a therapeutic candidate, MR191-N, which is a monoclonal antibody derived from a person who survived Marburg disease. Monoclonal antibodies are immune system fighters designed to bind to a specific part of an invading virus or bacterium to treat disease. The authors report that two doses of MR191-N were able to confer protection of up to 100 percent when treatment was started up to 5 days post infection. Prior studies of different experimental Marburg treatments involved daily dosing for 7 and 14 days, respectively, with treatment beginning closer to the time of infection.


The study was led by scientists at the University of Texas Medical Branch Galveston National Laboratory and Mapp Biopharmaceutical, Inc., and included collaborators from Vanderbilt University Medical Center, the University of Natural Resources and Life Sciences in Austria, and The Scripps Research Institute. The NIH’s National Institute of Allergy and Infectious Diseases (NIAID) provided project funding.


The researchers are now working with NIAID’s preclinical services group to perform the additional safety testing necessary to advance the monoclonal antibody treatment to initial human clinical studies. Public health workers learned during the 2014-15 Ebola outbreak in West Africa that lack of available treatment options kept diseased and at-risk people away from treatment centers, making disease tracking and outbreak containment more difficult. They fear the same situation would develop in a large-scale Marburg outbreak.


This article has been republished from materials provided by NIH. Note: material may have been edited for length and content. For further information, please contact the cited source.

Reference

C. Mire, et al. Therapeutic treatment of Marburg and Ravn virus disease in nonhuman primates with a human monoclonal antibody. Science Translational Medicine DOI:  10.1126/scitranslmed.aai8711 (2017).
Advertisement